4.6500
0.0000
(0.00%)
At close: January 29 at 3:00:00 PM EST
Breakdown
TTM
1/31/2024
1/31/2023
1/31/2022
1/31/2021
Operating Expense
3,026,698.0000
4,539,729.0000
7,899,308.0000
6,620,883.0000
5,801,739.0000
Operating Income
-3,026,698.0000
-4,539,729.0000
-7,899,308.0000
-6,620,883.0000
-5,801,739.0000
Net Non Operating Interest Income Expense
-30,334.0000
-32,847.0000
-124,208.0000
-52,560.0000
-100,618.0000
Pretax Income
-1,869,433.0000
-2,542,135.0000
-4,697,443.0000
-4,560,423.0000
-3,211,497.0000
Tax Provision
296,499.0000
102,196.0000
862,141.0000
117,433.0000
174,378.0000
Net Income Common Stockholders
-2,165,934.0000
-2,644,332.0000
-5,559,584.0000
-4,677,856.0000
-3,385,875.0000
Diluted NI Available to Com Stockholders
-2,165,934.0000
-2,644,332.0000
-5,559,584.0000
-4,677,856.0000
-3,385,875.0000
Basic EPS
-31.99
-40.48
-95.99
-90.33
-65.38
Diluted EPS
-31.99
-40.48
-95.99
-90.33
-65.38
Basic Average Shares
67,200.2860
65,322.6520
57,918.1660
51,789.1360
51,785.1020
Diluted Average Shares
68,630.3290
65,322.6520
57,918.1660
51,789.1360
51,785.1020
Total Operating Income as Reported
-3,026,698.0000
-4,539,730.0000
-7,899,308.0000
-6,620,884.0000
-5,801,740.0000
Total Expenses
3,026,698.0000
4,539,729.0000
7,899,308.0000
6,620,883.0000
5,801,739.0000
Net Income from Continuing & Discontinued Operation
-2,165,934.0000
-2,644,332.0000
-5,559,584.0000
-4,677,856.0000
-3,385,875.0000
Normalized Income
-2,328,289.2000
-2,915,772.0000
-5,560,746.8000
-4,791,353.3440
-5,688,541.6960
Interest Income
2,110.0000
2,465.0000
4,010.0000
2,240.0000
2,470.0000
Interest Expense
9,195.0000
10,548.0000
25,270.0000
44,606.0000
47,170.0000
Net Interest Income
-30,334.0000
-32,847.0000
-124,208.0000
-52,560.0000
-100,618.0000
EBIT
-1,860,238.0000
-2,531,587.0000
-4,672,173.0000
-4,515,817.0000
-3,164,327.0000
EBITDA
-1,849,420.0000
-2,517,083.0000
-4,647,558.0000
-4,383,350.0000
-3,089,872.0000
Reconciled Depreciation
10,818.0000
14,504.0000
24,615.0000
132,467.0000
74,455.0000
Net Income from Continuing Operation Net Minority Interest
-2,165,934.0000
-2,644,332.0000
-5,559,584.0000
-4,677,856.0000
-3,385,875.0000
Total Unusual Items Excluding Goodwill
211,400.0000
282,750.0000
1,425.0000
147,783.0000
3,318,920.0000
Total Unusual Items
211,400.0000
282,750.0000
1,425.0000
147,783.0000
3,318,920.0000
Normalized EBITDA
-2,060,820.0000
-2,799,833.0000
-4,648,983.0000
-4,531,133.0000
-6,408,792.0000
Tax Rate for Calcs
0.0002
0.0000
0.0002
0.0002
0.0003
Tax Effect of Unusual Items
49,044.8000
11,310.0000
262.2000
34,285.6560
1,016,253.3040
1/31/2021 - 10/12/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BOVNF BioInvent International AB (publ)
4.7000
0.00%
HNSBF Hansa Biopharma AB (publ)
3.0000
0.00%
GNNSF Genscript Biotech Corporation
1.3550
0.00%
MLLCF Molecular Partners AG
4.2800
0.00%
ASCLF Ascletis Pharma Inc.
0.2393
0.00%
PBIGF Paradigm Biopharmaceuticals Limited
0.3280
+10.85%
OXBDF Oxford Biomedica plc
5.56
0.00%
TRGNF Transgene SA
1.5900
0.00%
VBIZF Viva Biotech Holdings
0.0950
0.00%
IPHYF Innate Pharma S.A.
2.9000
0.00%